CV Dr.-Ing. Guenter Braun
From 2010 to 2012 Aristo Telemed had developed a telemedicine-supported method for the diagnosis
and treatment of the Chronic Kidnev Disease (CKD) at early stages in a project that had been partially
funded by the Bavarian Health Ministry. The development was based on literature by the National
Kidney Foundation (USA), USRDS Annual Data Reports, NHS (UK) reports and medical guidelines
from different countries as well as discussions with a family doctor in Ingolstadt and nephrologists in
Ingolstadt and Munich. Later it had been refined and translated to English.
In December 2019 Guenter Braun had a phone call with Aristo Telemed’s representative in the United
States who suggested to submit our proposals for CKD first to Canadian provinces. After that he will
be available to address private insurances in the United States and finally the Centers for Medicare
and Medicaid Services.
Guenter Braun had also established excellent contacts to Canada supported by the Canadian trade
commissioner to Germany and based on Alberta-Bavaria workshops in Munich 2018 and 2019.
Canada also seemed to be interested to participate in the harmonization of social laws in the EU
based on the free trade agreement CETA between Canada and the European Union
In January 2020 he had been asked by the Centers of Medicare and Medicaid Services to nominate
himself for a CMS Expert Panel for the development of a Quality Measure Assessing Delay in
Progression of the Chronic Kidney Disease at Yale University which he did. That had also been part of
the project for the Bavarian Health Ministry.
In March 2020 he started to submit proposals for a telemedicine-supported method for the diagnosis
and treatment of the Chronic Kidney Disease at early stages to governments of Canadian provinces.
Regarding the „Digitization” in healthcare and care for elderly persons, Aristo Telemed (AT) supported
and in many cases still supports startups and established companies from Canada, Germany,
Hungary, Israel, Latvia, Poland, Russia, Ukraine and the USA regarding international healthcare
market access for
a fall sensor for seniors, that provides an alarm to a predefined phone in case of an
unintended fall.
a method for non-invasive treatment of ADHD in children who show verbal and learning
deficits
an intelligent electronic stethoscope for use by an MD or at home that is synchronized with a
smartphone e.g. for the early detection of lung infections. It analyzes the recorded sounds,
can detect abnormalities and transmits the sounds and its suggested diagnosis to the patient’s
MD for further consultation.
An innovative RFID chip that can be attached to medical devices and surgical instruments
which tolerates high temperatures that are applied in sterilization processes. That chip helps
personnel in hospitals to find medical devices and surgical instruments in hospitals easier.
Worn on a bracelet by patients it helps finding those patients in hospitals if required.
An innovative method to investigate arteries and veins in order to avoid heart attacks and
strokes.
Further health apps e.g. for the support of psychiatric patients will follow soon.
A comparative study regarding different methods for an early detection of prostate cancer had
been prepared together with medicine professors in Cologne, Aachen and Hamburg will be
started soon. A high-ranking member of the German organization to which we will submit it
had already told me that they intend to fund that research as soon as the request will be
submitted.
In 2013 Guenter Braun had developed and proposed a modern governing structure for the German
Health system but nobody seemed to be interested. So he decided to become a candidate for the
elections to the European parliament 2019 and was nominated as a candidate by the CSU in
November 2018. In April 2019 Guenter Braun had discussed differences between the Austrian and
German Social Laws with the deputy director of the Main Association of Austrian Social Security
Institutions whom he had known since the introduction of the e-card in Austria in 2005 and the joint
participation at the WSIS 2005 in Tunis in autumn 2005. However, he did not believe that the German
or Austrian social law can be a role model for other EU countries. He had been invited to the upbeat of
the election campaign in Schrobenhausen on April 29th 2019 with Manfred Weber (the leader of the
E.P.P.) and Prof. Angelika Niebler for the elections to the European parliament. He had been
interviewed on stage in front of some 1,000 CSU members and said he would like to harmonize social
laws in the EU member states to avoid barriers in the European Economic Area so that all EU member
states can participate equally in advances in healthcare. In detail he suggested to introduce a modern
management structure in European healthcare based on goals similar to what he had developed and
introduced successfully with his team at Siemens AG worldwide almost 20 years ago and which
(business development) and he had lectured at Munich University and the University for Applied
Sciences Cologne from 2012 to 2018.
Even though the instruments (e.g. balanced scorecards) are the same, the goals in healthcare would
not be profit or company value but the quality of life and the healthy life years of the population in the
EU member states.
That was very well received by the audience. Later he supported Manfred Weber and Angelika Niebler
in their campaign with these personal goals (in German) that he sent to all Bavarian MDs networks,
hospitals, health insurers and medium-sized companies and achieved an excellent result for the CSU
in Bavaria. At the end of the rally event for the European parliament in Munich with Manfred Weber
and several European heads of state to which he was invited again, Angelika Niebler told him that we
will soon meet again (in Brussels). In October 2019 the office of the EU commission asked him to
apply with his professional CV as an advisor to the EU commission which he did. Since that time he
has been in contact with Ursula von der Leyen (the EU President) and Manfred Weber. However,
since early autumn 2020 he has been in contact with the WHO, who had in a few cases supported him
finding WHO member states with no or very few COVID-19 cases. Therefore, and because Canada
had also been very interested in the harmonization of social and healthcare legislation, and as he had
meanwhile submitted proposals to many states outside Europe he decided to offer the harmonization
of social and healthcare laws to the WHO to cover all of their member states. It is based on a modern
management structure based on goals and target agreements for the quality of life and measured in
healthy life years for all countries worldwide.
Still another project will also be started soon. Its purpose is to make sure that a patient can at all times
reach his family doctor by telephone. This is particularly important with single practices in rural areas
and could certainly be exported to many countries.
In April 2009 Dr. Braun founded the Aristo Telemed AG (AT). He holds all 50,000 shares of the
company.
In 2008 Dr. Braun was elected head and project manager of the National German Project Group
„ProTelemonitoring“ at the VDE in Frankfurt with all important stakeholders of the industry, including
several large health insurers, university hospitals, MDs, the German Health Ministry, and the federal
joint committee who decides what German health insurers must compensate. The project group
determined the benefits of telemedicine/telemonitoring support for patients with severe chronic
diseases in a metastudy for the BMBF (German Ministry for Education and Research). The evaluation
of benefits and proposals for the compensation of telemedicine were provided for diabetes, chronic
heart failure, chronic wounds and COPD. A brochure with the results can be obtained from the VDE.
In 2007 he left Siemens as ICN Enterprise Systems should be sold to an unknown buyer. It had
already significantly reduced investments and development expenses and had sold its campus in
Santa Clara/California to achieve a positive result. A separate spin-off of his group that would have
been financed by a well-known international investor based on a positive due diligence was opposed
by his peer as it was said that Healthcare Solutions was „the pearl of the company“, and without it ICN
Enterprise Networks could not be sold at all. Two meetings with the Siemens president Heinrich von
Pierer were positive but he said he needed to ask the board of directors for their consent. The
following meeting of the board of directors end of January 2007, however, was focused on the
Siemens bribery affair only and did not decide about the sales of the Healthcare Solutions Unit. So he
and also all members of his team left Siemens.
In 2002 he had suggested his peer to start a new business field at Siemens ICN Enterprise Networks
that should care about the upcoming use of ICT in healthcare systems. His boss reacted promptly and
asked him to build and lead the new unit. If he did he could be relieved of some of his other
responsibilities to date as he wanted. He also got permission to hire suitable personnel from any
Siemens organization for his new unit. The new business unit “Healthcare Solutions” started
operations beginning of 2003 while he kept contact with the universities (CAMPUS), Fraunhofer and
the eFinance Lab, and the Siemens customers as much as possible. Responsibilities of the global
Business Unit Healthcare Solution were business planning, turnover, and results as well as the
support of 40 national Siemens ICN units regarding customer support, sales, project management,
and services. Talks and negotiations with high-ranking deciders of governments or important health
institutions, e.g. the government of Slovenia, the US Department of Health and the speaker of the
House of Representatives Newt Gingrich in Washington D.C. USA on interoperability issues between
European and US electronic health records, the board of Health Infoway Canada in Toronto, the
Director of the NSW Cabinet Office Roger Wilkins in Sydney, the Director of Health in New Orleans Dr.
Kevin Stephens, and the board of the VHA Southwest in Dallas were part of his job. In New Orleans
he had been interviewed by Lousiana TV together with his US team member and Dr. Stephens
regarding the benefit of electronic health cards which was transmitted nationwide. For his stays in the
US he had an office in Malvern, Pennsylvania. Since 2002 he had also been involved with the
introduction of eHealth (HealthIT) in Germany (eGK, ePA), Austria (ecard) and Switzerland. In that
context he had also met several top politicians from different German “Bundesländer” including Ursula
von der Leyen at different fairs. At that time she was Minister for Health in Niedersachsen. For his
regular talks with the German Health Ministry he could use a Siemens office in Berlin at the
Gendarmenmarkt. In November 2005 he represented Siemens together with a member of the
Siemens board at the World Summit on IT in Tunis (WSIS 2005).
In 2000 he had been selected by Siemens ICN for leading a new field “innovation management” at the
division for cooperation with universities and research organizations that was regarded necessary by
the Siemens board. Focus was on Germany and the US, e.g. Georgia Tech Atlanta, SCR Princeton,
UC Berkeley and others. He gave a well-received lecture on his experience with business consultants
at the Wharton Business School (University of Pennsylvania). Together with different Siemens board
members he became a member of the steering committees of the technical universities Munich and
Berlin, met regularly with several German universities and research organizations, e.g. Fraunhofer
(CAMPUS-Meetings). He became also responsible for the evaluation of innovative ideas by startup
companies for Siemens Venture Capital. There was a partial overlap of these tasks with his
responsibility for business strategy.
1997 he joined the business communications division of Siemens where he became responsible for
business strategy and business development. With his department, he was given global responsibility
for the Siemens ITC strategy in all countries where Siemens ICN operated. With his new department
he became responsible for market analysis, business strategy, strategic and operative planning,
business development, benchmarking, target agreements for all managers, and the development and
ongoing maintenance of balanced scorecards, internal and external communication of goals, strategy
and customer benefits as well as total quality management issues. His responsibility also included
presentations and discussions with Siemens customers and their worldwide organization JUST
(Joint Users of Siemens Technology). It included many large companies in various countries. In
particular he often met and discussed with Swiss enterprises including the Central Swiss Power Plants
and several large banks. He was also a founding member of the eFinance Lab at Frankfurt University.
From 1986 to 1997 he worked for Daimler-Benz Aerospace in the satellite business (Dornier Satellite
Systems, today Airbus Space and Defense) where he was responsible for advanced antenna and
microwave technologies, innovations, sales and strategy in satellite communications and earth
observation technologies, and planning of planetary missions (e.g. Cassini/Huygens) in two branches
of the company in Southern Germany. Regarding SAR antennas for earth observation and planetary
missions he negotiated with the JPL Pasadena. With his department, he led and submitted various
successful proposals to ESA/ESTEC, and the German Research Ministry regarding advanced satellite
antennas and microwaves. Within the EU he participated in COST (Cooperation in Science and
Technology) meetings in various EU countries.
He was also successful with a proposal to the US Department of Defense for planning a Space Shuttle
mission to test and establish a measurement method to detect the launch of missiles and rockets.
He also established mm-wave technologies at his department. On that basis his department
successfully submitted proposals for satellite missions for environmental measurements e.g. ozone
and trace gases in the atmosphere and on ground. Considering that various technologies for space
applications could also be used to solve challenges in other industries, he convinced the CEO to make
an according announcement in the company which led to several interesting results. The winner was
the usage of rotating SAR antennas on helicopters which was then built and tested by Eurocopter and
showed promising results for obstacle warning of helicopters even under bad weather conditions.
Therefore it had the potential to significantly reduce the number of fatal helicopter accidents often
caused by collisions with wires and other obstacles. The solution “Heliradar” was submitted by several
organizations to the German President’s office and selected as one of five candidates for the German
Future Award 1997 (Deutscher Zukunftspreis).
G. Braun published the results of his research in various national and international research
magazines and presented those on various international symposia in Europe and the US. On one of
these occasions he received the privilege of a personal guided tour through the Hughes Corp. in Los
Angeles. Hughes was the world’s largest satellite manufacturer, and the tour included the impressive
satellite integration facility. Finally, in 1997 he proposed a strategy to develop and market a new
generation of communication satellites and was supported by about 40 DSS executives, the German
Research Ministry and the DSS employee organization. As the CEO denied to accept the strategy and
as he had a good job offer from Siemens, he left Dasa/DSS (1997).
From 1982 to 1986 he worked as a Research Fellow and Associate Professor at the University of the
Bundeswehr in Neubiberg near Munich. His research and development activities included mobile
communications, radar and medical technologies. For his research on noise optimization of oscillators
in mobile communications and radar systems he received the Dr.-Ing. degree with summa cum laude
in 1985. He presented his findings at the 1986 lEEE International Symposium on Circuits and Systems
in San Jose/California.
1974 to 1982 he worked for Siemens in Munich. Before he started 1977 working for Siemens in the
development of radio relay systems (2 to 15 GHz) and research on innovative semiconductor chips for
radio systems (MMICS etc.), Siemens had offered him a two-year trainee program (Ingenieurkreis)
where he was given the opportunity to work in different divisions of the company which he could
choose himself. Starting 1974, he chose to work on new semiconductor and printed circuit
technologies, the product management of a new radio relay system, and the sales of radio relay
systems in Africa and Southeast Asia. Negotiations with customer organizations took place in London
and Tripolis/Libya. He left Siemens 1982 to proceed with research work on his intended Dr.-Ing.
degree.
Guenter Braun had studied Electrical and Electronics Engineering at the Technical University Munich,
Germany and Southampton University, UK. He received the Dipl.-Ing. degree with summa cum laude
in 1974. He had received a scholarship from the Studienstiftung des deutschen Volkes.
Besides his job, in 1977 he founded a model railway shop in Munich that he led successfully until
2009. The shop had 3 to 5 employees and worldwide suppliers and customers in many countries of
the EU but also in the USA, Hongkong, Japan and China.
Publications, Miscellaneous:
- Over 50 scientific publications and conference lectures regarding communications and space
technology, Total Quality Management (EFQM, ISO9001), innovation management, HealthIT
und Telemedicine/Telemonitoring.
- Author, co-author and editor of professional books and brochures regarding aerospace
research, HealthIT and Telemonitoring.
- Member of the selection committees of the Studienstiftung des deutschen Volkes and the
Max-Weber-Programm for the award of scholarships for highly gifted students.
- 1986 Development of a research report for the Bavarian State Chancellery for funding of a
Bavarian startup enterprise regarding microwave technology.
- Nomination for the Deutscher Zukunftspreis of the German President Herzog 1997 with the
project HeliRadar.
- Since 2002 member of the research committee, the operative steering body of the Muenchner
Kreis, responsible for Healthcare and member of the working groups digitization and mobility
- Head of the program committees and chairman of the HealthIT congress February 2005 and
the conference Telemonitoring in July 2009 in Munich und Member of the program committee
for the preparation of the conference Digitizing and Big Data in Healthcare May 2018 in
Munich.
- From winter term 2012 until 2018 lectures regarding HealthIT infrastructure and Applications
as well as business development (e.g. for hospitals) in the extra-occupational master and
bachelor courses at the University for Applied Sciences Cologne and 2013 also at the
bachelor course Health Economics at Munich University.
- 2017-2018 he received a contract for a Research Report from the Technology Agency of
Latvia (LIAA) for the „European Regional Development Program“ regarding the development
funding of a Latvian startup enterprise.
- From 1977 to 2011 he had been member of the board of directors of the Muenchner
Baugenossenschaft in Muenchen-Laim with some 1000 flats, 20 years thereof until 2010 as its
chairman.
Saatja: Günter Braun <
[email protected]>
Saadetud: 02.03.2021 15:24
Adressaat: SM Info <
[email protected]>; <
[email protected]>; <
[email protected]>
Koopia: <
[email protected]>; 'Kräuter Kai' <
[email protected]>;
<
[email protected]>
Teema: Proposal for a Clinical Study regarding the telemedicine-supported diagnosis and
treatment of the Chronic Kidney Disease - Second Update and other issues
Manused: Estonia_Proposal for a study regarding the diagnosis and treatment of the Chronic
Kidney Disease at early stages-20-70-10.pdf; Project Information on the Clinical Study regarding
the telemedicine-supported diagnosis and treatment of CKD at early stages.docx; 2020-03-12 CV
Detailed CV english with Photo complete.pdf
Dear Sir or Madam,
Please forward this mail to
the Estonian Minister of Health and Social Affairs Mr. Kiik
and
the WHO director Europe Dr. Hans Henri Kluge
and
the Estonian Minister of Rural Affairs Mr. Urmas Kruuse
Dear Sir or Madam,
Initially our Proposal for a Clinical Study regarding the telemedicine-supported diagnosis and treatment
of the Chronic Kidney Disease had been submitted on 25.08.2020 when COVID-19 cases in Estonia were
very low. A complete update followed on 08.12.2020.
The proposal for a Clinical Study regarding the telemedicine-supported diagnosis and treatment of the
Chronic Kidney Disease at early stages means an effective treatment of the triggering diseases diabetes
and hypertension. We suggest that at the beginning of the study your ministry selects and nominates the
Estonian participants based on current diagnoses of diabetes and hypertension by MDs or hospitals.
Based on the last proposal from December 2020 the nomination may already in an advanced state or
the selection of participants will be easily achieved based on available electronic medical records that
you ministry may have.
As part of the telemedicine-supported study is the monthly transmission of the status of the triggering
diseases diabetes and hypertension to their local physicians and to Aristo Telemed (for the evaluation of
the study), the participants of the study should have access to a personal computer or a smartphone.
Even most elderly persons have that today.
Due to the relatively large number of study participants in Estonia we suggest an option to allocate them
to several groups with up to 1,000 participants each based on the severity of their triggering diseases. In
that case we further suggest to work consecutively on those groups starting with the group with the
most severely affected persons. If it will turn out, however, that the number of nominated participants is
less than 2,000, one group including all participants will also be feasible.
Regarding Canada and the United States for which the study had initially been developed, our
representative in the United States for which the study had initially been developed, our representative
in the United States had told me recently that the COVID-19 pandemic there will not allow a successful
submission of the proposal there before the beginning of 2021 or even later. That has meanwhile been
confirmed by the actual situation there. As the situation in several (but not all) European countries, New
Zealand, Australia, Vietnam, Singapore and several others was much better at the time of submission
there we had submitted our individualized proposals there first.
From the ministry of an EU member state we had received congratulations for the study design. The
study allows participants an effective telemedicine-supported treatment
Of diabetes and hypertension. It will thus make sure that a possible later infection with COVID-19 will not
lead to a life-threatening situation. In a recent scientific publication on a study it had been mentioned
that the COVID-19 virus loves to stay and multiply in the kidneys.
As already mentioned above, the first step to begin with is the selection and nomination of the study
participants. In order to comply with data protection and privacy rules we suggest that your ministry
provides the Estonian participants with pseudonyms EST1, EST2, EST3, etc. Finally I would like to add that
the study is compliant with the harmonization of the health legislations in the EU and other WHO
member states to be performed by me and my team later this year.
The goal for the harmonization of health legislations in the EU and other WHO member states mean that
all countries use the same modern management structure based on goals and target agreements. That
had originally been developed for industrial companies and was implemented by me and my team about
20 years ago at Siemens ICN. Then the goals were profit and several others which were important for
business development. Balanced scorecards were used for reporting. I case of healthcare goals will be
primarily healthy life years of the population and secondarily their life expectancy. That can be achieved
with better and earlier prevention.
Exactly that is intended with the telemedicine-supported diagnosis and treatment of CKD at early stages,
i.e. the triggering diseases diabetes and hypertension to avoid the development of costly kidney
replacement therapies like dialysis or a new kidney from a suitable donor.
Prof. Voicehovska (interal diseases) at Stradins University Riga had meanwhile asked an had received
additional project information that was based on a template by Fiji Research. The project information,
the proposal, and my detailed professional CV are attached to this mail.
Assuming that you use electronic medical records or similar means, the nomination of the study
participants should be completed within about three weeks. Therefore we suggest a validity of the
proposal until 26.03.2021. If you need a prolongation, please let me know in time.
In case of a contract we will after that date proceed offering the Ministry of Rural Affairs Estonia a new
farming method that will provide an up to 30 per cent higher yield than today. That had been invented in
Europe and we had signed a Cooperation Contract with the inventor some time ago. The method had
already been tested successfully in Europe and besides the higher yield it will also have the potential to
help reaching the Paris goals for our planet’s climate change.
We look forward to working with you.
Best regards
Guenter Braun
Dr. Guenter Braun
President and CEO
Aristo Telemed AG
Edmund-Mueller-Str. 2
D-82041 Oberhaching
Tel. +49 89 6252818
Fax +49 89 6252719
Mob. +49 171 5573686
[email protected] and
[email protected]
Proposal for a study regarding the diagnosis and treatment of the Chronic Kidney Disease at early
stages, i.e. the diagnosis and treatment of the triggering diseases Diabetes and Hypertension.
Aristo Telemed had developed that in a project that had been partially funded by the Bavarian Health
Ministry 2010-2012 based on literature by the National Kidney Foundation (USA), USRDS Annual
Reports, NHS reports and medical guidelines from different countries regarding diagnosis and
treatment of CKD and discussions with a family doctor in Ingolstadt and nephrologists in Ingolstadt
and Munich.
Estonia 2020 population is estimated at 1,326,535 people at mid-year according to UN data.
Prevalance of diabetes in Estonia:
Estonia is one of the 57 countries of the IDF EUR region. 463 million people have diabetes in the
world and more than 59 million people in the EUR Region; by 2045 this will rise to 68 million.
Total adult population of Estonia: 948,700
Prevalence of diabetes in adults : 6.2%
Total cases of diabetes in adults : 58,700
Prevalence of Hypertension in Estonia:
Among European countries Estonia stands out with high prevalence of hypertension, affecting more
than one third of adult population.
Overall, 36% of participants had hypertension, with approximately 80% being aware of their
condition. A total of 40% of participants reported taking antihypertensive medication.
Diabetes and Hypertension are also triggering diseases for the Chronic Kidney Disease (CKD). CKD is a
severe disease that does not hurt and can therefore often develop almost unnoticed to higher stages
with enormous consequences for the patient. Therefore it makes a lot of sense to treat CKD at early
stages in a telemedicine-supported project. Telemedicine will support the patient in his or her
endeavour to avoid the development of CKD to higher stages and other severe diseases.
Diabetes and Pre-Diabetes are in most cases be treated by lifestyle, exercise, and dietary changes so
that only a fraction of those require medical treatment. Regarding the non-adherence rate, e.g. in
Latvia probably less than 4,000 people would be affected. As both Diabetes, Pre-Diabetes and
Hypertension may cause CKD, the number of patients who require medical treatment cannot finally
be provided. So this proposal can only provide the cost per patient.
Regarding the use of antihypertensive drugs, Prof. John Toon (GeorgiaTech Atlanta) had recently
published a research report in the journal Lancet that Thiazide diuretics demonstrate better
effectiveness and cause lower side effects than ACE inhibitors.
The following cost per patient will apply. They are based on proposals by the respective companies:
Medipense is located in Quebec, Canada, Beurer is located in Germany.
Medipense Automatic Dispenser € 3,250.00
supports the adherence of the patient to the prescription
of his family doctor or specialist doctor.
Cost for each patient including RxPense, initial training and
deployment, configuration, monitoring, support and
management for a period up to one year After that period
annual maintenance and support is 20%
Beurer Bluetooth Upper Arm Blood Pressure Monitor for
Self-testing per patient € 20.43
Beurer Bluetooth Glucose Monitor for self testing
Cost per unit € 18.02
Test strips € 6.87
Lancets € 1.29
Overall cost of Beurer equipment per patient € 46.61
The values for blood pressure and glucose are regularly measured by the patient, e.g. once a month
and transmitted via the patient’s smartphone to his/her family doctor or nephrologist and
To Aristo Telemed for the evaluation of the study.
Cost of Aristo Telemed for project management and evaluation of the project results
€ 263.25
Overall cost of the study per patient € 3,559.86
Above cost are payable to Aristo Telemed IBAN: DE56 7007 0024 0886 9182 00
BIC: DEUTDEDBMUC
They are due as follows:
20% with the order by the customer
70% when the devices have been delivered to the Estonian Ministry of
Health and Social Affairs for distribution to participating patients
10% when the study has been evaluated
All cost by equipment manufacturers will be paid by Aristo Telemed when the devices have been
delivered to the Health Ministry of Estonia for distribution to the patients participating in the study
to their accounts upon sending an invoice to Aristo Telemed by mail or email.
Based on our experience with previous clinical studies in Europe we suggest
An operational time of the study 12 months
Measurements of glucose and blood pressure monthly
The medicines for the treatment are prescribed by the patient’s physician and provided by
pharmacies in blisters which are compliant with the Medipense dispenser.
To comply with data protection and privacy rules the names and addresses of patients are not
needed or used in the study. Instead we propose to use pseudonyms like EST1, EST2, EST3, etc.
which are allocated to the patients and may be used by Aristo Telemed for the evaluation of the
study. Only the Ministry of Health Estonia knows the personal data behind the pseudonyms.
Dr. Guenter Braun
President and CEO
Aristo Telemed AG
Edmund Mueller Str. 2
D-82041 Oberhaching
Tel. +49 89/6252818
Fax +49 89/6252719
Mob. +49 171/5573686
[email protected] and
[email protected]
Project Information on the Clinical Study regarding the telemedicine-supported diagnosis and treatment of the Chronic Kidney Disease at early stages Background information: Diabetes and Hypertension are the triggering diseases for the Chronic Kidney Disease (CKD). They need to be treated early enough to avoid the further development of CKD which may end in the requirement to treat the patient with dialysis or to provide a kidney replacement for the affected patient – both very expensive alternatives. A kidney replacement would also require the availability of a suitable donor. Statement of the problem: As diabetes and hypertension are common diseases in most populations which are often overlooked as they do not hurt but if not treated will have serious consequences for the affected patients. Therefore timely treatments of diabetes and hypertension are required to avoid an escalation to CKD. Review of literature etc.: The basic literature regarding CKD had been reviewed in a project partially funded by the Bavarian Health Ministry. That was based on literature by the National Kidney Foundation (USA), USRDS Annual reports, NHS reports, and medical guidelines from different countries regarding diagnosis and treatment of CKD and discussions with a family doctor in Ingolstadt and nephrologists in Ingolstadt and Munich. Furthermore my personal experience included my father-in-law who had inherited a shrink kidney and had been on dialysis for several years before he finally died from kidney failure in February 2014. Aims and Objectives, Methodology: As a consequent and regular diagnosis and treatment of diabetes and hypertension is required to avoid an escalation t o CKD, telemedicine-support is required to make sure that the affected patients adhere to the prescriptions of their local physicians. Therefore, the actual status of their diabetes and hypertension is transmitted monthly to their local physicians and to Aristo Telemed (for the evaluation of the study). Data collection plan, monitoring, processing and analysis: The data collection is provided monthly through well-known and established devices which support the patient in his adherence to the physician’s prescription and measure the actual values of blood pressure and glucose. Those values are transmitted to the patients’ PC or smartphone via Bluetooth technology for the further transmission to the patients’ local physician and to Aristo Telemed . In this way all important information can be collected month ly. The project management and the final evaluation is provided by Aristo Telemed AG as we have a huge experience in that field . Ethical consideration, administration, utilization of results: The project supports patients in their endeavor to avoid escalations of the CKD to higher stages and the consequences of such an escalation. The participating patients are selected and nominated by the Ministry of Health based on recent diagnoses of diabetes and hypertension. The results will be provided to the Ministry of Health in a report after the project duration of 12 months. The research team will involve : Dr. Guenter Braun , Dr. Dijana Naumoska, and possibly Dr. Susanne Braun More information has been or is provided in the specific proposals.